4DMedical Limited unveiled its innovative CT:VQ technology at RSNA 2024, offering a revolutionary alternative to traditional Nuclear VQ scans, aiming to enhance diagnostic capabilities in lung health. The new imaging solution eliminates the use of radioactive isotopes, streamlining procedures while improving patient access and safety. This advancement could potentially disrupt the over $1 billion market for Nuclear VQ diagnostics in the U.S., with clinical trials underway and an FDA submission targeted for mid-2025. The collaboration with Philips was also highlighted, emphasizing the partnership’s role in elevating diagnostic precision and addressing respiratory health challenges, particularly for veterans.